Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Labianca

Showing results (131-140 of 166) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?A Sobrero, A Grothey, T Iveson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 26, 2009
Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected databaseM Mandalà, G L Imberti, D Piazzalunga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2010
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trialR Labianca, A Sobrero, L Isa, et al.
Cancer Detection and Prevention|April 2, 1999
Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term resultsM C Locatelli, G Facendola, G Pizzocaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotypeV Bazan, M Migliavacca, I Zanna, et al.
British Journal of Cancer|April 20, 2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancerA Sobrero, A Guglielmi, M Cirillo, et al.
Anticancer Research|November 2, 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter surveyA Mancuso, S Sacchetta, P C Saletti, et al.
British Journal of Cancer|March 1, 2002
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimenS Cascinu, A M Baldelli, V Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2015
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialE Rulli, M Marabese, V Torri, et al.
Lancet (London, England)|September 12, 1998
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer ResearchP Rougier, T Sahmoud, D Nitti, et al.
Pageof 17

Showing results (131-140 of 166) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?A Sobrero, A Grothey, T Iveson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 26, 2009
Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected databaseM Mandalà, G L Imberti, D Piazzalunga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2010
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trialR Labianca, A Sobrero, L Isa, et al.
Cancer Detection and Prevention|April 2, 1999
Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: long-term resultsM C Locatelli, G Facendola, G Pizzocaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotypeV Bazan, M Migliavacca, I Zanna, et al.
British Journal of Cancer|April 20, 2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancerA Sobrero, A Guglielmi, M Cirillo, et al.
Anticancer Research|November 2, 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter surveyA Mancuso, S Sacchetta, P C Saletti, et al.
British Journal of Cancer|March 1, 2002
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimenS Cascinu, A M Baldelli, V Catalano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2015
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialE Rulli, M Marabese, V Torri, et al.
Lancet (London, England)|September 12, 1998
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer ResearchP Rougier, T Sahmoud, D Nitti, et al.
Pageof 17